drugset / Trial / NCT05398861
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
Phase 2
Recruiting
79 enrolled
Henan Cancer Hospital
Beijing Biostar Pharmaceuticals Co., Ltd. · collabQilu Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, single-arm, open-label phase II study to evaluate the efficacy and safety of the combination of Utidelone and bevacizumab regimen in patients with ≥ 2 lines of HER-2 negative advanced breast cancer.
Timeline
- Start
- 2022-08-19
- Primary completion
- 2026-12-30
- Completion
- 2027-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Epothilone D | Small molecule | 30 mg/m2 | Intravenous |